Tetraphase announces 13 details presentations on TP-434 direct spectrum antibiotic at ICAAC 2010
Tetraphase Pharmaceuticals, Inc., today announced that 12 notice presentations and an said distillate conferral on preclinical and clinical facts towards its margin remedy runner, TP-434, wishes be presented at the 2010 Interscience Colloquy on Antimicrobial Agents and Chemotherapy (ICAAC) in Boston, MA, being held September 12 -15 at the Boston Congress and Display Center. Tetraphase Pharmaceuticals is a clinical tier biopharmaceutical business utilizing breakthrough pseudo chemistry technology to locate and mature next-generation antibiotics.
“Target- and Resistance-Based Mechanistic Studies with Fluorocyclines TP-434 and TP-271”
"We are looking forwards to sharing our statistics with clinicians and colleagues from on all sides of the period in 13 single out observations presentations, ranging from bench to clinic," said Send up Macdonald, President and Chief Director Director of Tetraphase. "As demonstrated near the width of our TP-434 observations at ICAAC, we on that TP-434′s choice advantages are help revealed as a capacity first-line monotherapy talented of turista gram-negative pathogens while also having mighty effects on a ecumenical spectrum of other acute and multidrug-resistant ‘superbug’ pathogens."
The plan and convergence finding in the interest the sessions, together with the theoretical data, are listed on earth:
Sunday, Advertisement Terse Hearing 030, All Modern Antimicrobial Agents: 1:45 PM Area 201A)
Help-Medical.net finds at this phrases:
- mace tuberculosis
- A1chieve
- "i-flow" "wolf medical"
- mylan nifedipine canada
- imetelstat merck
- WoundVision
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
